XUANZHUBIO-B (02575.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec8

Xuanzhu Bio-B's Anelarazole Sodium Enteral Tablet Renewed for Inclusion in the 2025 National Basic Medical Insurance Drug List

04:18

Xuanzhu Biotech's Innovative Drug First Included in the 2025 National Medical Insurance Directory

04:15

Oct28

Xuanzhu Biopharma's Introduced NG-350A Receives FDA Fast Track Designation

08:40

Oct21

Xuanzhu Bio-B Displays Mid-Stage Results of Pyrolisib Combined Treatment for Breast Cancer in Phase III Clinical Trial

22:29

Oct18

Multiple Biotech Companies Complete Financing and Technology Licensing, Innovative Pharma Debuts on Hong Kong Exchange

02:02

Oct6

XUANZHUBIO-B released FY2024 Q2 earnings on October 6, 2025 (BJT), with actual revenue of HKD 8.612 M and EPS of HKD -0.1323

15:00

Schedules & Filings

Schedules

Filings

Oct15

IPO(CST)

Listing Price HKD 11.6

Oct6

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 9.792 M, Net Income -60.7 M, EPS -0.1346

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More